key: cord-0901301-g4zmzsfb
authors: Tang, Li; Cherry, Sean; Tuomanen, Elaine I; Roubidoux, Ericka Kirkpatrick; Lin, Chun-Yang; Allison, Kim J; Gowen, Ashleigh; Freiden, Pamela; Allen, E Kaitlynn; Su, Yin; Gaur, Aditya H; Estepp, Jeremie H; McGargill, Maureen A; Krammer, Florian; Thomas, Paul G; Schultz-Cherry, Stacey; Wolf, Joshua
title: Host predictors of broadly cross-reactive antibodies against SARS-CoV-2 variants of concern differ between infection and vaccination
date: 2021-12-10
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab996
sha: 66844b8dd2fa2382ac9928df3408fe61edf4abdc
doc_id: 901301
cord_uid: g4zmzsfb

BACKGROUND: Following SARS-CoV-2 infection or vaccination there is significant variability between individuals in protective antibody levels against SARS-CoV-2, and within individuals against different virus variants. However, host demographic or clinical characteristics that predict variability in cross-reactive antibody levels are not well-described. These data could inform clinicians, researchers, and policy makers on the populations most likely to require vaccine booster shots. METHODS: In an institutional review board-approved prospective observational cohort study of staff at St. Jude Children’s Research Hospital, we identified participants with plasma samples collected after SARS-CoV-2 infection, after mRNA vaccination, and after vaccination following infection, and quantitated IgG levels by ELISA to the spike receptor binding domain (RBD) from five important SARS-CoV-2 variants (Wuhan Hu-1, B.1.1.7, B.1.351, P.1 and B.1.617.2). We used regression models to identify factors that contributed to cross-reactive IgG against one or multiple viral variants. RESULTS: Following infection, a minority of the cohort generated cross-reactive antibodies, IgG antibodies that bound all tested variants. Those that did had increased disease severity, poor metabolic health, and were of a particular ancestry. Vaccination increased the levels of cross-reactive IgG levels in all populations including immunocompromised, elderly and persons with poor metabolic health. Younger people with a healthy weight mounted the highest responses. CONCLUSIONS: Our findings provide important new information on individual antibody responses to infection/vaccination that could inform clinicians on the populations that may require follow-on immunization.

Since its emergence in December 2019, there have been >198 million cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with over 4.2 million deaths (WHO) [1] . Viral evolution has caused considerable genetic change compared to the original SARS-CoV-2 Wuhan Hu-1 strain [2] . These genetic changes include substitutions within the functional domains of the viral spike (S) protein leading to altered biological properties, including increased transmissibility, enhanced binding to the human ACE2 receptor, and increasing virulence [2] . Important variants of concern (VOCs) and B.1.617.2 (Delta), detected in India in October 2020 [3] . As the virus continues to mutate, a better understanding of the breadth of the antibody response following infection or vaccination is critical for future vaccine design and public health interventions.

Studies have focused on assessing antibody responses to a specific VOC or set of samples, for example convalescent patients or vaccine recipients [4] [5] [6] . These studies found reduced binding and neutralization against variants, further exemplified by a comprehensive study [7] examining antibody potency against all VOC using convalescent samples from patients with varying disease severity, and mRNA vaccine recipients, and another showing that vaccination increases all components of the humoral response [8] . However, individual IgG responses differ, and recent studies showed that serum from convalescent patients display variable neutralization capacities [9] . It remains unclear whether specific host characteristics predict antibody breadth and magnitude against the VOCs.

To fill this knowledge gap, we used ELISA to quantitate IgG titers against RBD from SARS-CoV-2 Wuhan Hu-1, B. 

Authors confirm all relevant data are included in the paper and/or supplementary files.

The St. Jude Tracking of Viral and Host Characteristics Associated with COVID-19 study (SJTRC, NCT04362995) is a prospective, institutional review board-approved, longitudinal cohort study of adult (≥18 years of age) employees at St. Jude Children's Research Hospital initiated in March, 2020. Participants provided written informed consent, completed questionnaires about demographics, medical history, treatment, and symptoms, and a severity questionnaire following PCR-confirmed SARS-CoV-2 infection. Participants were screened for SARS-CoV-2 by nasal swab PCR weekly when on campus, and convalescent blood was collected approximately 3-8 weeks after SARS-CoV-2 infection and/or vaccination. Blood samples were separated into cellular and plasma components within 24 hours of collection and stored at -80C. Severity of disease was dichotomized as: severe or critical (dyspnea, or requiring supplemental oxygen, hospital admission, or dialysis during the COVID-19 episode) vs. others. BMI was self-reported, classified according to CDC criteria and dichotomized as obese or very obese (BMI ≥30) vs others [10] .

Immunocompromise included all immunocompromising conditions as reported by participants, including autoimmune diseases, antibody deficiency and corticosteroid use (Supplementary Table 1 ). Participants who had completed a full course of BNT162b2 by the data freeze were included in post-vaccine cohorts.

A c c e p t e d M a n u s c r i p t 7

Purified SARS-CoV-2 Wuhan Hu-1, B.1.1.7, B.1.351, P.1, and B1.617.2 RBD proteins, expressed in 293T cells as described [11, 12] , were diluted to a concentration of 1.5 µg/ml in phosphate buffered saline (PBS) and added at 50 µl per well to a 96-well ELISA plate (Immulon 4 HBX; Thermo Fisher Scientific). The ELISA plates were sealed and allowed to incubate at 4ºC overnight as described [12] . The next day the coating solution was removed, and the plates were blocked at room temperature using 3% non-fat milk prepared in PBS (200 µl per well) for 1-4 hours. While the plates were being blocked, the samples were prepared by diluting the heat-inactivated plasma 1:50 in 1% milk. Following blocking, the milk was removed, and the plates washed three times with PBS containing 0.1% Tween-20 (PBST) at 200 µl per well. The diluted plasma was added to the blocked plate at 50 µl per well and incubated for 1.5 hours at room temperature and then removed and washed 3x with 200 µl 0.1% PBST. Goat anti-human IgG horseradish peroxidase (HRP) conjugated secondary antibody (Thermo Fisher Scientific) was diluted 1:2500 in 1% milk and 50 µl was added to each well of the washed plate and incubated at room temperature for 30 minutes.

Following the incubation period, the secondary was removed, and the plate was washed 3x with 0.1% PBST. SIGMAFAST OPD (o-phenylenediamine dihydrochloride; Sigma-Aldrich) substrate was prepared directly before use and added at 50 µl per well for exactly 8 minutes.

The OPD substrate was stopped by adding 50 µl of 3M Hydrochloric acid. The optical density at 490 nm (OD490) was measured using a Synergy 4 (BioTek) plate reader. SARS-CoV-2 reactive human monoclonal antibody CR3022 [11] at 1:5000, 1:25000, 1:125000, and 1:625000 dilutions and plasma from naturally infected donors at a 1:50 dilution) and known negative, pre-pandemic plasma samples diluted at 1:50 were used as controls. The background value was set at an OD490 of 0.15 as previously described. [11] Samples with an OD490 two-times greater than background, or ≥0.3, were considered positive as this value has been suggested as a surrogate for the presence of neutralizing antibodies in the same assay. [12] A c c e p t e d M a n u s c r i p t 8

Adiponectin and leptin concentrations were measured in heat inactivated plasma diluted at 1:50 or 1:5000 using the R&D Systems Leptin and Adiponectin DuoSet ELISA respectively per manufacturer's protocol. An adiponectin:leptin ratio >1.0 was defined as a low-risk for adipose tissue dysfunction or metabolic syndrome, >0.5-<1.0 moderate-risk, and <0.5 high-risk [11, [13] [14] [15] . For the statistical analyses, the ratio was dichotomized as highrisk vs. others.

This study comprised a convenience subcohort of 399 participants from the larger study with 581 relevant samples selected to represent important antigen-exposure paradigms. Although not prospectively powered for this objective, this analysis had >80% power to detect an OD fold-change ≥1.3 or ≤0.77, using a t-test with coefficient of variation A c c e p t e d M a n u s c r i p t 9 of infection (before or after 10/1/2020), were considered as covariate candidates. The date cutoff 10/1/2020 was selected arbitrarily as being between the first and second epidemic waves in Memphis, TN. The elastic net model selection method [18] , which extends the LASSO method[19] and ridge regression [20] , was carried out with the BIC criterion [21] applied. For analysis of cross-reactivity only, samples with an OD value ≥0.3 were considered positive as this value has been suggested as a surrogate for the presence of neutralizing antibodies in the same assay. [22] Cross-reactivity was defined as the presence of antibodies (OD ≥0.3) against Wuhan Hu-1 or B.1.1.7, plus either B.1.351 or P.1 variants.

Multivariate logistic models were implemented to analyze cross-reactivity, with a similar model selection strategy. Multivariate linear or logistic mixed models were also attempted, but were not included because estimates were very close, and the BIC criterion consistently favored the former. A two-sided p-value <0.05 was considered significant. Statistical analyses were performed in SAS software, version 9.4 (SAS Institute Inc.) and R software, version 4.0.2 (R Foundation for Statistical Computing). Table 1, and Supplementary Tables 1 and 2 , and were similar to the overall cohort.

A c c e p t e d M a n u s c r i p t 10 Most participants with SARS-CoV-2 infection had mild or moderate illness with viruses derived from Wuhan-like viruses or B.1 derivative lineages that did not contain known markers of substantial antigenic effect (Supplemental Table 9 ). Severe or critical COVID-19 was associated with immunocompromise (OR=6.9; P=0.016) and obesity (BMI≥30, OR=2.7; p=0.0095). Lower Adp:Lep ratio also correlated with disease severity ( Table 2 ); 70% of participants with critical or severe disease had Adp:Lep <0.5, signifying adipose tissue dysfunction. There was no association with gender, race, age, ethnicity, or patient contact (Table 2 and Supplementary Table 3 )

To define factors underlying the magnitude and breadth of the IgG response against 

Hierarchical clustering was used to identify factors underlying the cross-reactive antibodies.

We classified individual VOC RBD IgG titers to infection ( The host characteristics that resulted in lower VOC IgG responses post-vaccination included obesity, time since vaccination, and older age ( Figure 5 ). Further work is needed to define the mechanism(s) for the reduced IgG levels.

This study addresses a critical, unresolved question about IgG responses to SARS-CoV-2 infection and/or vaccination at an individual leveldefining the characteristics associated with a lower cross-reactive IgG response against SARS-CoV-2 VOCs. We which is in keeping with the literature [23, 24] . Published studies have shown that antibodies from late convalescence or following more severe disease exhibited increased neutralization potency to VOCs, suggesting persistence of cross-neutralizing plasma IgG levels. Age, gender and immunocompromise had no significant effect on IgG levels after infection. If confirmed in other studies, the finding that moderate immunocompromise was not associated with decreased antibody responses to any of the variants would be reassuring for immunocompromised individuals. The lack of association between disease severity and gender was surprising since a male bias in COVID-19 mortality has been reported [25] . This may be due to the limited number of participants with severe disease. There was also no sex bias associated with overall difference in IgG responses, consistent with one other study [26] .

Although we found an association between race and IgG levels, the construct is confounded by many social factors, so it is difficult to determine the relevance or mechanism of this finding.

We also demonstrated that high BMI or a low Adp:Lep ratio indicating adipose tissue dysfunction and metabolic syndrome was associated with more severe disease, which parallels other studies [27, 28] . However, following infection-only poor metabolic health (Adp:Lep ratio <0.5) was associated with higher IgG responses against VOCs. This was an A c c e p t e d M a n u s c r i p t 14 independent factor unrelated to disease severity, and is consistent with others postconvalescent wild-type SARS-CoV-2 neutralizing antibody levels in individuals with metabolic syndrome comorbidities. [29] The reason for the association is unclear. Increased systemic inflammation caused by the metabolic syndrome might lead to higher antibody responses or, alternatively, these individuals might shed virus longer leading to increased immune stimulation. [30] Vaccination resulted in plasma antibodies against VOCs that are mostly comparable to the anti-RBD ELISA titers against the original Wuhan Hu-1 strain. While the levels of cross-reactive IgG against RBD from multiple SARS-CoV-2 variants following vaccination were significantly associated with younger age, healthy weight, being a male and more recent vaccination, vaccination improved IgG levels in all groups. Although the finding that being overweight was associated with lower antibody responses to most variants following vaccination is in stark contrast to antibody levels following infection in participants with the metabolic syndrome, it is clearly consistent with other data suggesting that patients with obesity have poorer responses to other vaccines, such as influenza. [31] Overall, this study identifies factors influencing the magnitude and breadth of the IgG response to the spike RBD of 4 important SARS-CoV-2 VOCs. Limitations include the relatively low number of patients with critical illness or immunocompromised status, completion prior to widespread emergence of the delta variant, and use of ELISA rather than neutralization titers. However, we have previously demonstrated that samples with an ELISA OD < 0.3 have no neutralizing activity [12] . Further, this OD cutoff was defined in the original protocol as being the difference between samples that would be positive and negative against the spike protein [11] . These data could help prioritize vaccines and boosters for individuals expected to have the lowest antibody levels. 

The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays (the -Serology Assays‖) and NDV-based SARS-CoV-2 vaccines which name FK as a co-inventor; FK would also like to note the following, which could be M a n u s c r i p t M a n u s c r i p t 23 

World Health Organization. Coronavirus disease (COVID-19) pandemic

SARS-CoV-2 Variants and Vaccines

World Health Organization. Tracking SARS-CoV-2 variants

Detection of a SARS-CoV-2 variant of concern in South Africa

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Antibody evasion by the P.1 strain of SARS-CoV-2

Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities

A serological assay to detect SARS-CoV-2 seroconversion in humans

Jude Investigative Team. Choosing the right tool for the job: A comprehensive assessment of serological assays for SARS-CoV-2 as surrogates for authentic virus neutralization

Adiponectin-leptin ratio: A promising index to estimate adipose tissue dysfunction. Relation with obesityassociated cardiometabolic risk

Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio

Adiponectin/leptin ratio and insulin resistance in pregnancy

Statistical software for the design, simulation and monitoring clinical trials

Hierarchical Grouping to Optimize an Objective Function

Regularization and variable selection via the elastic net

Regression shrinkage and selection via the lasso

Ridge regression

Estimating the dimension of a model

An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization

Disease severity and durability of the SARS-CoV-2 antibody response: A view through the lens of the second year of the pandemic

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants

Considering how biological sex impacts immune responses and COVID-19 outcomes

Sex-based clinical and immunological differences in COVID-19

Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract

Metabolic Syndrome and Viral Pathogenesis: Lessons from Influenza and Coronaviruses

Postconvalescent SARS-CoV-2 IgG and Neutralizing Antibodies are Elevated in Individuals with Poor Metabolic Health

Persistence of SARS-CoV-2 RNA in a male with metabolic syndrome for 72 days: A case report

Increased risk of influenza among vaccinated adults who are obese

correlation as the distance measure for transformed OD values and Euclidean distance for all 24 covariates was applied. SARS-CoV-2 infection was used as a split variable in clustering

The authors wish to thank the members of the Thomas, McGargill, and Schultz-Cherry labs for technical assistance and feedback on the work. The authors also thank Gang Wu and the 

A c c e p t e d M a n u s c r i p t 19 A c c e p t e d M a n u s c r i p t